Sign in

CIK 0001776111

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

MBX Biosciences, Inc.

Sign in to watch
Ticker
MBX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 317-989-3100
Business address
11711 N. MERIDIAN STREET, SUITE 300, CARMEL, IN, 46032
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$288,361
in 2 filings

Net −$288,361. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2026-05-06 Hawryluk P. Kent President & CEO Sale −607 $29.54 $18K 727,667
2026-03-13 Hawryluk P. Kent President & CEO Purchase +18,500 $28.41 $526K 486,777
2026-02-26 Hawryluk P. Kent President & CEO Exercise or conversion +28,768 $16.00 $460K 728,274
2026-02-26 Hawryluk P. Kent President & CEO Exercise or conversion · Stock option (right to buy) −28,768 91,668
2026-02-02 Hawryluk P. Kent President & CEO Grant or award +35,250 699,506
2026-02-02 Hawryluk P. Kent President & CEO Grant or award · Stock option (right to buy) +164,500 164,500
2025-10-24 Hawryluk P. Kent President & CEO Exercise or conversion +182,859 $3.25 $594K 664,256
2025-10-24 Hawryluk P. Kent President & CEO Exercise or conversion · Stock option (right to buy) −182,859 129,708
2025-10-20 Hawryluk P. Kent President & CEO Purchase +20,000 $13.64 $273K 468,277
2025-02-04 Hawryluk P. Kent President & CEO Purchase +50,000 $10.69 $535K 448,277
2025-02-03 Hawryluk P. Kent President & CEO Grant or award · Stock Option (Right to Buy) +243,000 243,000
2024-09-16 Hawryluk P. Kent President & CEO Conversion +283,846 481,397
2024-09-16 Hawryluk P. Kent President & CEO Conversion +115,914 398,277
2024-09-16 Hawryluk P. Kent President & CEO Conversion · Series A Convertible Preferred Stock −2,015,681 0
2024-09-16 Hawryluk P. Kent President & CEO Conversion · Series A Convertible Preferred Stock −345,705 0
2024-09-16 Hawryluk P. Kent President & CEO Conversion · Series B Convertible Preferred Stock −1,396,762 0
2024-09-16 Hawryluk P. Kent President & CEO Conversion · Series B Convertible Preferred Stock −76,969 0
2024-09-16 Hawryluk P. Kent President & CEO Conversion · Series C Convertible Preferred Stock −970,873 0
2024-09-12 Hawryluk P. Kent President & CEO Grant or award · Stock Option (Right to Buy) +120,436 120,436

Page 1 of 1 · 19 trades